在瑞典复发缓解型多发性硬化或临床孤立综合征患者中比较利妥昔单抗与富马酸二甲酯的安全性和疗效:一项评价者盲法、3期、随机对照试验
RIFUND-MS是一项在瑞典17家医院开展的多中心、评价者盲法、活性对照、3期随机对照试验,纳入200例早期复发缓解型多发性硬化或临床孤立综合征患者,1:1随机接受利妥昔单抗(1000 mg后每6个月500 mg静脉给药)或富马酸二甲酯(240 mg口服每日两次)。利妥昔单抗组3% vs 富马酸二甲酯组16%出现方案定义的复发(RR 0.19,95%CI 0.06-0.62;p=0.0060)。
要点
- 利妥昔单抗组3% vs 富马酸二甲酯组16%出现方案定义复发,RR 0.19(95%CI 0.06-0.62;p=0.0060)。
- 利妥昔单抗组最常见不良事件为输注反应(105起事件,40.9/100患者年)。
- 富马酸二甲酯组最常见不良事件为胃肠道反应和潮红(各65起事件,47.4/100患者年)。
核心结论
- RIFUND-MS提供证据表明,在早期复发缓解型多发性硬化患者中,利妥昔单抗1000 mg后每6个月500 mg方案在24个月内预防复发优于富马酸二甲酯。
- 作者认为需要开展利妥昔单抗用于多发性硬化患者的卫生经济学和长期安全性研究。
研究设计与样本
- RIFUND-MS为多中心、评价者盲法、活性对照、3期随机对照试验,在瑞典17家大学和社区医院开展。
- 纳入标准:年龄18-50岁;根据现行McDonald标准诊断为复发缓解型多发性硬化或临床孤立综合征;确诊10年或以内;未治疗或仅暴露于干扰素或醋酸格拉替雷;过去一年有临床或神经放射学疾病活动。
- 治疗医师使用瑞典多发性硬化登记系统的随机化模块自动1:1随机分配,无分层,至口服富马酸二甲酯240 mg每日两次或静脉利妥昔单抗1000 mg后每6个月500 mg。
- 复发评估、扩展残疾状态量表评分和MRI扫描评估由对治疗分配设盲的检查医师和放射科医师完成。
- 主要结局为至少一次复发的患者比例,在意向性治疗分析中使用对数二项回归及稳健标准误评估。
主要发现
- 2016年7月1日至2018年12月18日筛查322例患者,200例随机分配(利妥昔单抗组100例,富马酸二甲酯组100例)。
- 利妥昔单抗组98例和富马酸二甲酯组97例符合主要结局分析条件。
- 利妥昔单抗组3例(3%)vs 富马酸二甲酯组16例(16%)在试验期间出现方案定义的复发,风险比0.19(95%CI 0.06-0.62;p=0.0060)。
- 利妥昔单抗组输注反应(105起事件[40.9/100患者年])和富马酸二甲酯组胃肠道反应(65起事件[47.4/100患者年])及潮红(65起事件[47.4/100患者年])为最常见不良事件。
- 未观察到安全性问题。
关键数值与推荐
- 利妥昔单抗组3% vs 富马酸二甲酯组16%出现方案定义复发,风险比0.19(95%CI 0.06-0.62;p=0.0060)。
- 利妥昔单抗组输注反应105起事件(40.9/100患者年);富马酸二甲酯组胃肠道反应65起事件(47.4/100患者年)和潮红65起事件(47.4/100患者年)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: B-cell depleting therapies are highly efficacious in relapsing-remitting multiple sclerosis but one such therapy, rituximab, is not approved for multiple sclerosis and no phase 3 trial data are available. We therefore examined the safety and efficacy of rituximab compared with dimethyl fumarate in patients with relapsing-remitting multiple sclerosis to obtain data that might allow inclusion of rituximab in treatment guidelines. METHODS: RIFUND-MS was a multicentre, rater-blinded, active-comparator, phase 3, randomised controlled trial done at 17 Swedish university and community hospitals. Key inclusion criteria for participants were: age 18-50 years; relapsing-remitting multiple sclerosis or clinically isolated syndrome according to prevailing McDonald criteria; 10 years or less since diagnosis; untreated or only exposed to interferons or glatiramer acetate; and with clinical or neuroradiological disease activity in the past year. Patients were automatically randomly assigned (1:1) by the treating physician using a randomisation module in the Swedish multiple sclerosis registry, without stratification, to oral dimethyl fumarate 240 mg twice daily or to intravenous rituximab 1000 mg followed by 500 mg every 6 months. Relapse evaluation, Expanded Disability Status Scale rating, and assessment of MRI scans were done by examining physicians and radiologists masked to treatment allocation. The primary outcome was the proportion of patients with at least one relapse (defined as subacute onset of new or worsening neurological symptoms compatible with multiple sclerosis with a duration of more than 24 h and preceded by at least 30 days of clinical stability), assessed in an intention-to-treat analysis using log-binomial regression with robust standard errors. This trial is registered at ClinicalTrials.gov, NCT02746744. FINDINGS: Between July 1, 2016, and Dec 18, 2018, 322 patients were screened for eligibility, 200 of whom were randomly assigned to a treatment group (100 assigned to rituximab and 100 assigned to dimethyl fumarate). The last patient completed 24-month follow-up on April 21, 2021. 98 patients in the rituximab group and 97 patients in the dimethyl fumarate group were eligible for the primary outcome analysis. Three (3%) patients in the rituximab group and 16 (16%) patients in the dimethyl fumarate group had a protocol-defined relapse during the trial, corresponding to a risk ratio of 0·19 (95% CI 0·06-0·62; p=0·0060). Infusion reactions (105 events [40·9 per 100 patient-years]) in the rituximab group and gastrointestinal reactions (65 events [47·4 per 100 patient-years]) and flush (65 events [47·4 per 100 patient-years]) in the dimethyl fumarate group were the most prevalent adverse events. There were no safety concerns. INTERPRETATION: RIFUND-MS provides evidence that rituximab given as 1000 mg followed by 500 mg every 6 months is superior to dimethyl fumarate in preventing relapses over 24 months in patients with early relapsing-remitting multiple sclerosis. Health economic and long-term safety studies of rituximab in patients with multiple sclerosis are needed. FUNDING: Swedish Research Council.
引用
- Svenningsson A, Frisell T, Burman J, et al. Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial. Lancet Neurol. 2022. PMID: 35841908. doi:10.1016/S1474-4422(22)00209-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。